

Crowe supports healthcare specialists GENUI and SHS Capital with investment in ROTOP
ROTOP Pharmaka GmbH, founded in 2000 and based in Rossendorf near Dresden, is a market leader in the manufacture of radiopharmaceutical products. The company's roots lie in the former Central Institute for Nuclear Research Rossendorf, which developed into one of the leading radiopharmaceutical centers in the world from 1958. ROTOP manufactures cGMP-compliant radiopharmaceuticals for diagnostics and therapy in the fields of nuclear medicine and molecular imaging and distributes them in more than 40 countries worldwide. With around 170 employees, ROTOP is continuously expanding its range by developing new products and new strategic partnerships.
Two years ago, ROTOP started to expand its CDMO offering in order to meet the increasing demand and to be able to cover the clinical and commercial need for batch capacities in the future. With the investment from GENUI and SHS Capital, the existing CDMO capacities are now to be significantly expanded, among other things. Thanks to ROTOP's ties to the region, WMS Wachstumsfonds Mittelstand Sachsen has also been won as an investor.
BPG Beratungs- und Prüfungsgesellschaft mbH (Crowe BPG) advised GENUI and SHS Capital on the transaction. The Crowe BPG team (crowe-bpg.de) that conducted the financial due diligence consisted of Andreas Hoffmann (auditor and managing director (overall management)), Martin Brinkfort (Senior Manager, Financial) and Philipp Jans (Senior Associate, Financial).
Source: Deal Advisors by Majunke